Thursday, 9 September

The White Hall of the University of Tartu Museum (click to see the venues in GoogleMaps)

18.30 - 22.00

Welcome reception
Opening speeches

Prof Jaanus Harro 

Prof Lembit Allikmets

►Plenary lecture
History of Chemistry in University of Tartu
Prof Enn Lust, University of Tartu

Friday, 10 September

University of Tartu main building (click to see the venue in GoogleMaps)

8.15 - 8.20

►Opening
 Prof Toomas Asser,  Rector of the University of Tartu

8.20 - 9.05

►Plenary lecture
Pharmacogenetics in psychopharmacology: approaches of individualization
Prof Ingolf Cascorbi, Kiel University, President of International Union of Basic and Clinical Pharmacology (IUPHAR)

►Neuropsychopharmacology 1

The legacy of Arvid Carlsson: the past, present and future of psychopharmacology
Prof Elias Eriksson, University of Gothenburg

MANF in cortex development and therapeutic implications for stroke
Prof Mikko Airavaara, University of Helsinki

Personalized psychopharmacology of psychostimulants: reward sensitivity in animals and humans
Prof Jaanus Harro, University of Tartu and North Estonia Medical Centre

Novel RNA methylation regulating compounds protect and regenerate dopamine neurons
Prof Mart Saarma, University of Helsinki

►Recent Advancements in Drug Design and Delivery

Nanocrystal based formulations in drug delivery
Prof Leena Peltonen, University of Helsinki

Peptide-based transfection: applications in biotechnology for the production of therapeutic proteins
Dr Kaido Kurrikoff, University of Tartu  

Identification and testing of new treatment targets in neuropsychiatric disorders
Prof Jan Haavik, University of Bergen, Norway

Preclinical and clinical development of vascular homing peptides for precision medicine
Prof Tambet Teesalu, University of Tartu

Safety and biocompatibility of electrospun nanofiber mats as wound matrices
Kaisa Põhako, Msc, University of Tartu

13.45-17.00

►Oncology

Pharmacogenomics of tyrosine kinase inhibitor resistance
Prof Ingolf Cascorbi, Kiel University, President of International Union of Basic and Clinical Pharmacology (IUPHAR)

Precision medicine in oncology - where we are? 
Dr Kersti Oselin, North Estonia Medical Centre

The role of neurotrophic factors in nerve and cancer crosstalk
Dr Anu Planken, North Estonia Medical Centre and University of Tartu

Current state of art - cancer immunotherapy in clinical practice 
Dr Ann Valter, North Estonia Medical Centre

Future of cancer immunotherapy in experimental research 
Prof Pärt Peterson, University of Tartu

Cancer immunotherapy in early clinical development 
Dr Aidi Adamson-Raieste, North Estonia Medical Centre and The Christie Hospital, Manchester 

Endocrine side effects of new oncological drugs
Dr Ingrid Reppo, University of Tartu

13.45-15.45

►Network for European Clinical Trials for Children

From microsampling to miniature mass spectrometers - advances in bioanalysis with limited sample volume
Dr Karin Kipper, University of Tartu, Epilepsy Society, Head of Therapeutic Drug Monitoring Unit, UK

The effects of augmented renal clearance on the pharmacokinetic profile of antibiotics
Dr Lenne-Triin Kõrgvee, Tartu University Hospital, University of Tartu

Measurement of glomerular filtration rate using iohexol
Dr Hiie Soeorg, University of Tartu

Vancomycin and DosOpt 
Dr Riste Kalamees, Tartu University Hospital, University of Tartu

Pharmacokinetics  of spironolactone in children under 2 years
Dr Jana Lass, Tartu University Hospital, University of Tartu 

Pharmacokinetics and concentration related effects of dobutamine in neonates
Dr Maarja Hallik, East Tallinn Central Hospital, University of Tartu

15.00-18.30

►Emerging drugs in Endocrinology and Diabetes

Development of cagrilintide, a long-acting amylin analogue
Dr Kirsten Raun, NovoNordisk, Denmark

Acute and Chronic Metabolic effects of Melatonin
Prof Ulla Kampmann Opstrup, Steno Diabetes Center Aarhus and Aarhus University

Citrulline - more than just an amino acid
Prof Alastair Forbes, Norwich Medical School, University of East Anglia, the UK and University of Tartu

16.25-16.40  Coffee break

New drugs for osteoporosis
Prof Ugis Gruntmanis, Geisel School of Medicine at Dartmouth,USA

17.10 Short communications

Development of tolerance toward effects of GLP-1 receptor agonists
Dr Tuuli Sedman, University of Tartu

GLP-1 receptor agonists affect other hormonal systems
Dr Keiu Heinla, University of Tartu

New drugs for the treatment of hypercortisolism
Dr Kristina Isand, University of Tartu

Saturday, 11 September

University of Tartu main building (click to see the meeting point in GoogleMaps)

8.20 - 8.50

►Plenary lecture

Pharmacovigilance: from reactive to proactive and predictive
Prof Lembit Rägo, Secretary-General of Council for International Organizations of Medical Sciences (CIOMS)

►Plenary lecture

Can dysregulated myelination be linked to ADHD pathogenesis and does this generate new treatment targets?
Prof Klaus-Peter Lesch, University Hospital of Würzburg

9.20 - 11.00

►New Challenges in Medicine

Changing patterns of the COVID-19 pandemic
Prof Irja Lutsar, University of Tartu

Lessons learned during the pandemic season 2020/21 and implications for the future
Prof Uga Dumpis, Pauls Stradins Clinical University Hospital, Latvia

Spread of COVID-19 from aerosol physics point of view
Prof Heikki Junninen, University of Tartu

Advanced Therapy Medicinal Products (ATMP)
Prof Toivo Maimets, University of Tartu

►Neuropsychopharmacology 2

The potential of neuropeptides in psychopharmacology - insights from animal models
Prof David A. Slattery, Johann Wolfgang Goethe-Universität Frankfurt am Main

Epigenetics and Psychostimulant Addiction
Prof Anti Kalda, University of Tartu

Extended release naltrexone for opioid use disorders: Advantages and problems
Prof Evgeny Krupitsky, V.M. Bekhterev National Medical Center for Psychiatry and Neurology and First Pavlov Saint Petersburg State Medical University

Neuronal plasticity and neurotrophin signaling in the antidepressant effect
Prof Eero Castrén, University of Helsinki

►New drugs in Cardiology

How to combine antiplatelet and anticoagulant drugs?
Dr Alar Irs, Tartu University Hospital and Estonian State Agency of Medicines

How to minimize the risk of arrhythmia with QT-prolonging drugs?
Dr Jessica Schubert, Uppsala University Hospital

New drugs in dyslipidemia therapy
Dr Martin Serg, North Estonia Medical Centre

►Closing remarks